Seed Money Blossoming Again For Entrepreneurs

Although investors are more cautious than they were in the go-go 1980s, sources of early-round backing flourish anew After a four-year slump, venture capital funds that provide early-round financial support, including seed money, to start-up biotechnology companies and other high-tech enterprises are reportedly starting to flourish again. "On the order of 100 venture capital funds are currently raising money," says Robert Mast, vice president of Venture Economics, Newark, N.J., a unit of Sec

Written byJean Wallace
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

"On the order of 100 venture capital funds are currently raising money," says Robert Mast, vice president of Venture Economics, Newark, N.J., a unit of Securities Data Co. that tracks activity at the approximately 700 or so venture capital funds throughout the United States. "That's the highest number since 1987."

It's easier to attract a venture capital investment than it is to win your state lottery. But not by much. As a rule of thumb, venture capitalists fund roughly one out of every 100 business plans they read. Fortunately, you can do much to beat these odds. Here are some suggestions gleaned from a recent seminar on venture financing sponsored by the Technology Council of Greater Philadelphia. How do you find a venture capitalist? Ask for recommendations from successful entrepreneurs or use a referral network through a banker or other financial consultant. Also useful: Pratt's Guide to Venture Capital Sources, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies